BH3120: A novel bispecific antibody targeting 4-1BB and PD-L1 with well balanced efficacy and safety profiles.

被引：0
|
作者：
Xu, Jiangcheng [1 ]
Liu, Yang [1 ]
Wang, Jing [1 ]
Fan, Fei [1 ]
Gu, Haitao [1 ]
Zhang, Lanxin [1 ]
Wang, Jun [1 ]
Song, Ding [1 ]
Guo, Ailong [1 ]
Zhang, Hongjuan [1 ]
Su, Kaixuan [1 ]
Su, Jiaojiao [1 ]
Li, Lijuan [1 ]
Cai, Jingmei [1 ]
Zhang, Aihong [1 ]
Liu, Jiawang [1 ]
Lee, Kyoungwoo [1 ]
机构：
[1] Beijing Hanmi Res Ctr, Beijing, Peoples R China
来源：
CANCER RESEARCH | 2022年 / 82卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5605
引用
收藏
页数：1
相关论文
共 50 条
  • [31] A novel form of 4-1BB ligand has better efficacy than agonistic 4-1BB antibody as well as TLR agonists in a peptide based cancer vaccine
    Sharma, Rajesh K.
    Elpek, Kutlu G.
    Yolcu, Esma S.
    Schabowsky, Rich-Henry
    Zhao, Hong
    Bandura-Morgan, Laura L.
    Shirwan, Haval
    JOURNAL OF IMMUNOLOGY, 2009, 182
  • [32] Bispecific antibody targeting TGF-β and PD-L1 for synergistic cancer immunotherapy
    Li, Tianye
    Wang, Xinrun
    Niu, Mengke
    Wang, Mingli
    Zhou, Jianwei
    Wu, Kongming
    Yi, Ming
    FRONTIERS IN IMMUNOLOGY, 2023, 14
  • [33] OriA362: A promising CLDN18.2/4-1BB bispecific antibody for targeting pancreatic and gastric cancers with high efficacy and safety profile
    Yang, S.
    Wu, K.
    Shi, Z.
    Wang, H.
    Li, X.
    He, X.
    ANNALS OF ONCOLOGY, 2024, 35 : S157 - S157
  • [34] Dual targeting PD-L1 and 4-1BB to overcome dendritic cell-mediated lenalidomide resistance in follicular lymphoma
    Zheng, Zhong
    Wang, Jian-Biao
    Sun, Rui
    Wang, Nan
    Weng, Xiang-Qin
    Xu, Tian-Yuan
    Fu, Di
    Feng, Yan
    Xu, Peng-Peng
    Cheng, Shu
    Wang, Li
    Zhao, Yan
    Qu, Bin
    Huang, Chuan-Xin
    Zhao, Wei-Li
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2025, 10 (01)
  • [35] Discovery of a novel Claudin 6 X 4-1BB bispecific antibody with potent anti-tumor activity through conditional 4-1BB activation
    Li, Jian
    Jiang, Wenqing
    Liu, Yan
    Wang, Zhengyi
    Chen, Xi
    Guo, Taylor B.
    CANCER RESEARCH, 2022, 82 (12)
  • [36] Development of a novel bispecific antibody targeting PD-L1 and CD55 for cancer therapy.
    Chaudhary, Amit K.
    Shi, Jiadong
    Cai, Wenyan
    Wang, Bo
    Zaman, Mohd S.
    Huang, Cai
    Lin, Jun
    Kan, Steven Z.
    Zhou, Joe
    Dong, Jianbo
    Liu, Yue
    CANCER RESEARCH, 2021, 81 (13)
  • [37] A NOVEL ANTI-MSLN X 4-1BB BISPECIFIC ANTIBODY WITH FC EFFECT FUNCTION AUGMENTS THE ANTITUMOR EFFICACY
    Cheng, Liansheng
    Zhang, Dayan
    Zhang, Dayan
    Wu, Lingling
    Zhou, Weiming
    Zeng, Xiaoli
    Dai, Xuejing
    Liu, Wenting
    Zhao, Qun
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1259 - A1259
  • [38] A novel HER2/4-1BB bispecific antibody, YH32367 (ABL105) exhibits the optimal efficacy and superior safety profile through tumor-directed 4-1BB agonism
    Lee, Eunjung
    Chung, Hyejin
    Lee, Yangsoon
    Lee, Eun-Jung
    Park, Young Bong
    Park, Ju Young
    Ahn, Sujin
    Kim, Junhwan
    Ahn, Kyoung Kyu
    Park, Kyeongsu
    Son, Wonjun
    Yeom, Donghoon
    Jung, Jaeho
    Won, Jonghwa
    Oh, Se-Woong
    CANCER RESEARCH, 2022, 82 (12)
  • [39] A study on the efficacy and Safety Evaluation of a novel PD-1/CTLA-4 bispecific antibody
    Song, Qi
    Jiang, Meiling
    Pan, Xinrong
    Zhou, Guanyue
    Zhang, Xiaomeng
    IMMUNOBIOLOGY, 2024, 229 (06)
  • [40] Converting Tumoral PD-L1 into a 4-1BB Agonist for Safer and More Effective Cancer Immunotherapy
    Li, Zihai
    Azar, Joseph H.
    Rubinstein, Mark P.
    CANCER DISCOVERY, 2022, 12 (05) : 1184 - 1186
12345